Table 1.
Baseline Demographic and Clinical Data of the Study Population (n=1019)
| Variable | Total Sample (N=1019) |
|---|---|
| Age, y | 50±12 |
| Male sex | 640 (63%) |
| Hypertension | 454 (45%) |
| Diabetes mellitus | 120 (12%) |
| Family history of HCM | 172 (17%) |
| Family history of sudden cardiac death | 110 (11%) |
| History of sudden cardiac death | 6 (0.6%) |
| Unexplained syncope | 146 (14%) |
| History of nonsustained ventricular tachycardia | 112 (11%) |
| Beta‐blockers | 746 (73%) |
| Calcium‐channel blocker | 316 (31%) |
| Disopyramide | 42 (4%) |
| Angina | 143 (14%) |
| NYHA Class | |
| I | 296 (29%) |
| II | 526 (52%) |
| III/IV | 197 (19%) |
| Major HCM risk factors | |
| None | 766 (75%) |
| 1 | 225 (22%) |
| 2 or more | 28 (3%) |
| 5‐y ESC risk score (%) | 4.1±0.7 |
| ESC risk score categories | |
| Low (<4%) | 663 (65%) |
| Intermediate (4–6%) | 194 (19%) |
| High (>6%) | 162 (16%) |
ESC indicates European Society of Cardiology; HCM, hypertrophic cardiomyopathy; NYHA, New York Heart Association.